Browsing by Author "Pinto, V."

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Glucocorticoids Decrease Longitudinal Bone Growth in Pediatric Kidney Transplant Recipients by Stimulating the FGF23/FGFR3 Signaling Pathway
    (2019) Delucchi, A.; Toro, L.; Alzamora, R.; Barrientos, V.; Gonzalez, M.; Andaur, R.; Leon, P.; Villanueva, F.; Galindo, M.; Reyes General, Loreto; Heras, F.L.; Montecino, M.; Moena, D.; Lazcano, A.; Pinto, V.; Salas, P.; Mericq, V.; Michea, L.
  • Thumbnail Image
    Item
    Late Acute Humoral Rejection in Low-Risk Renal Transplant Recipients Induced With an Interleukin-2 Receptor Antagonist and Maintained With Standard Therapy: Preliminary Communication
    (ELSEVIER SCIENCE INC, 2011) Morales, J.; Contreras, L.; Zehnder, C.; Pinto, V.; Elberg, M.; Araneda, S.; Herzog, C.; Calabran, L.; Aguilo, J.; Ferrario, M.; Buckel, E.; Fierro, J. A.
    Low-risk renal transplant recipients treated with standard immunosuppressive therapy including interleukin-2 receptor (IL-2R) antagonist show a low incidence of early rejection episodes but few reports have examined the incidence and severity of late rejection processes. This study evaluated retrospectively cellular and antibody-mediated rejection (AMR) among 42 recipients selected because they showed low panel-reactive-antibodies, short cold ischemia time, no delayed graft function, and therapy including basiliximab (Simulect) induction. The mean observation time was 6.6 years. Sixty-seven percent of donors were deceased. Ten-year patient and death-censored graft survivals were 81% and 78%, respectively. Seven patients lost their kidneys due to nonimmunologic events. The seven recipients who experienced cellular rejection episodes during the first posttransplant year had them reversed with steroids. Five patients displayed late acute AMR causing functional deterioration in four cases including 1 graft loss. De novo sensitization occurred in 48% of recipients including patients without clinical rejection. In conclusion, long-term follow-up of kidney transplant recipients selected by a low immunologic risk showed a persistent risk of de novo sensitization evolving to acute AMR in 11% of cases. Although immunologic events were related to late immunosuppressive reduction, most graft losses were due to nonimmunologic factors.
  • No Thumbnail Available
    Item
    Latin American Registry of Pediatric Renal Transplantation 2004-2008
    (2010) Goulart, P.; Koch, P.; Medina-Pestana, J.; Garcia, C.; Bittencourt, V.; Medeiros, M.; Munoz, R.; Delucchi, A.; Lillo, A. M.; Ariza, M.; Bosque, M.; Carvalho, D.; Matuck, T.; Meneses, R.; Fontes, J.; Monteiro, D. C.; Neto, E. Davi; Pinto, V.; Salas, P.; Prates, L.; Belanguero, V.; Pereira, L.; Lima, E.; Penido, J. M.; Benini, V.; Laranjo, S.; Silva, J. M.; Orta, N.; Coronel, V.; Cisneros, A.; Arriaga, J.; Sebastian, M. J.; Abbud-Filho, M.; Fernandez, I.; Gastelbondo, R.; Medjia, N.; Rosati, P.; Hevia, P.; Baptista, M. A.; Ramalho, H.; Diaz, M.; Monteverde, M.; Ferraris, J.; Repetto, H.; Exeni, R.; Florentin, L.; Florin, J.; Cazorla, N.; Casadei, D.; Melendez, K.; Calderon, R.; Silva, V.; Patino, J.; Palacio, D.; Madrigal, G.; Sandoval, M.; Urbina, C.; Loza, R.; Cavagnaro, F.; Vogel, A.; Jimenez, W.; Lou, R.; Rodriguez, C.; Aguilar, C.; Galvez, H.; Rodriguez, L.; Paladini, J.; Agusti, J.; Puelma, F.; Troche, A.; Martinez-Pico, M.; Higueras, W.; Liendo, C.; Restrepo, J.; Caicedo, L. A.; Socorro, F.; Semprum, P.
    The Latin American Pediatric Nephrology Association (ALANEPE) reports the first regional kidney transplant registry in Latin America. A mean range of 75%, 30% to 100% renal transplant recipients under 21 yr old were included. Out of 20 countries invited to participate, 14 performed renal transplant, 11 had universal financial support from their governments. The centers included: Brazil (9), Argentina (4), Chile (4), Venezuela (3), Mexico (2), and one in: Cuba, Colombia, Costa Rica, Nicaragua, Guatemala, Ecuador, Honduras, Paraguay and Peru. The registry included 1458 patients, average of 291 per year, 55% male. Mean follow-up 23.4 +/- 17 months; mean age was 11.7 +/- 4.3 yr (1-21), 11% under five yr of age. Etiology: uropathy/ reflux nephropathy 27%, glomerulopathies 24% (included 12% FSGS), hypo/dysplasia (11%), vascular (6%), congenital/hereditary (5%), unknown (19%). Induction therapy: 71% anti-IL2RAb, 13% ATG/TIMO, 14% non-induction. Maintenance therapy: Tacrolimus 64%, Cyclosporine 32%, MMF 54%, MPS 20%, noTORi 96%, steroids 90%, withdrawal or steroid avoidance 10%. Loss of graft 155/1458 (11%), death with functioning graft (3.4%), vascular thrombosis (2.8%), acute rejection (2.8%), recurrence of disease (1%). Forty-eight patients died (3.3%); infection was the main cause 23 (2.1%). Global patient survival rate at one, three, and five yr was 97%, 96%, and 96%. Graft survival rate at one, three, and five yr LRD was 96%, 93% and 89%; for DD 92%, 86% and 76% respectively. Both survival rates were higher in LRD (p < 0.008 and p < 0.001). A pediatric renal transplant study has started, making information available to be shared between the centers and the world.
  • Thumbnail Image
    Item
    Steroid Withdrawal in Pediatric Kidney Transplant Allows Better Growth, Lipids and Body Composition : A Randomized Controlled Trial
    (2013) Mericq, V.; Salas, P.; Pinto, V.; Cano, F.; Reyes, L.; Brown, K.; González, M.; Michea, L.; Delgado, I.; Delucchi, A.